The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Cambridge Antibody Technology’s (CAT) general counsel Diane Mellett had a spectacularly busy 2004 handling the work relating to CAT’s major litigation against pharmaceutical giant Abbott Laboratories.
The contractual dispute centred on claims by CAT that Abbott had underpaid the royalties it owes to CAT for developing a rheumatoid arthritis drug. After months of preparation the case was heard before the High Court last December after the parties failed to resolve the dispute by mediation. On 20 December, Mr Justice Laddie handed Mellett an early Christmas present by ruling in CAT’s favour.
In addition, CAT’s sole in-house lawyer spent much of the second half of 2004 advising the company on its joint venture with AstraZeneca, which bought up 20 per cent of CAT’s shares.
Mellett has also been preparing CAT’s response to the Myners report on pre-emption rights. The Government-commissioned report, which was prepared by Marks & Spencer chairman Paul Myners, concluded that pre-emption rights are critical to the relationship between the company and its shareholders, but questions whether they have become too inflexible.